Skip to content


Tarceva (erlotinib) is a small molecule pharmaceutical. Erlotinib was first approved as Tarceva on 2004-11-18. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma and pancreatic neoplasms. The pharmaceutical is active against epidermal growth factor receptor. In addition, it is known to target solute carrier organic anion transporter family member 2B1.
Trade Name Tarceva
Common Name Erlotinib
Indication non-small-cell lung carcinoma, pancreatic neoplasms
Drug Class Tyrosine kinase inhibitors
Get full access now